Stem Cell Therapy Perspectives in Treating Motor Neuron Diseases: ALS and SMA
pipeline contains 7 R & D products undergoing development by 6 companies, all from the USA. Out of 7 products one product is in Phase I/II, three are in Phase I clinical trials, and three products are in preclinical stage of development. Six products are undergoing development for ALS, and one for ALS and SMA. The majority of adult stem cells used for the treatment of ALS and SMA are autologous, only one stem cells-based product is allotransplant. Patients own bone marrow was source of adult stem cells in four products, patients own skin in one product, fetal spinal cord tissue in one product, and embryonic stem cells in one product. Motor neurons were differentiated for use in two products. If there are no major setbacks, including alarming adverse effects, the publisher expects that this pipeline will progress relatively efficiently. Possible positive therapeutic effects of motor neuron cell-based products for the treatment of both ALS and SMA may be expected. When evaluating results of products in this pipeline, it is important to remember that alternative for patients is death, and any positive result will have enormous significance.
Key Topics Covered:
1. Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's Disease)
2. Spinal Muscular Atrophy (SMA Type I)
3. Brain, Spinal Cord and Neural Cells
4. Stem Cells
5. Embryonic Stem Cells
6. Engineered Stem Cells.
7. Effects of ALS and SMA on Blood-Brain Barrier and Adult Stem Cells
8. Stem Cell Therapy for Motor Neuron Diseases
9. Pipeline Analysis and Expectations
10. Products Profiles
11. Companies and Investors
12. Conclusion
For more information visit http://www.researchandmarkets.com/research/3a24b8/stem_cell_therapy